Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 4
1(50.0%)
2Total
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04300868Unknown

Immunisation Status and Safety of Vaccines in Italian MS Patients

Role: collaborator

NCT04871399Not ApplicableRecruiting

Complete Mesocolic Excision in Comparison With Conventional Surgery for the Right Colon Cancer

Role: collaborator

NCT04549831Recruiting

Genetic Bases of COVID-19 Clinical Variability

Role: collaborator

NCT00870038Phase 4Unknown

To Achieve an Early Reendothelialization at the Expense of Low Restenosis: The EREMUS Study

Role: lead

All 4 trials loaded